



## **NEW GAMMA KNIFE CENTER IN LISBON, PORTUGAL, ORDERS LEKSELL GAMMA KNIFE® PERFEXION™ FROM ELEKTA**

### **PRESS RELEASE**

Stockholm, Sweden, May 10, 2007

**Elekta today announced an order for Leksell Gamma Knife® Perfexion™, the latest and most advanced system ever for non-invasive radiosurgery of brain disorders, from Centro Gamma Knife Radiocirurgia S.A. This first Gamma Knife Center in Portugal will be established at Hospital CUF Infante Santo, a part of the Jose Mello-Saude Group.**

Centro Gamma Knife Radiocirurgia S.A. (CGKR) is a private initiative, established with the aim to bring this non-invasive, innovative technology to patients in Portugal. Leksell Gamma Knife Perfexion, scheduled to be in clinical operation by early fall 2007, will be installed in a new Gamma Knife Center that will be managed by CGKR together with Hospital CUF Infante Santo in Lisbon.

Hospital CUF Infante Santo is a well equipped private hospital with a long tradition and reputation for excellence in health care. The hospital is centrally located in Lisbon and the Gamma Knife Center will treat patients both from Portugal and from other countries.

"We are very pleased that we have been able to bring this amazing technology for non-invasive radiosurgery of brain disorders to Portugal. The creation of the new Gamma Knife Center at Hospital CUF Infante Santo will be a benefit for patients from the whole country," said Pedro Lucena e Valle, Chief Operating Officer at CUF. "We are very impressed with the performance of Leksell Gamma Knife Perfexion as has been shown by our colleagues in Marseille, France. With unlimited cranial reach and ability to also treat the cervical spine, we will be able to address malignant and benign brain tumors as well as other brain disorders with extreme precision and accuracy, giving patients a much less traumatic alternative to invasive surgery", ends Mr. Lucena e Valle.

Gamma Knife® surgery, also known as stereotactic radiosurgery, is a method for treating tumors and other brain disorders with ultra precise focused radiation, in many cases eliminating the need for invasive procedures. Contrary to invasive brain surgery, requiring many days of aftercare in the hospital, the patient normally leaves the hospital the same day and can return to normal life on the following day.

Leksell Gamma Knife Perfexion is a technological breakthrough incorporating a completely new and optimized design that will improve and expand Gamma Knife surgery while maintaining full clinical compatibility with Gamma Knife procedures and protocols based on over 400,000 treated patients.

The patented collimator design provides the neurosurgeon or radiation oncologist with almost unlimited ability for sculpting the dose to produce complex dose distributions with incomparable accuracy. Designed from the ground up with patient and staff comfort in mind, the high degree of automation offered by Leksell Gamma Knife Perfexion reduces treatment times to a minimum.



\*\*\*\*\*

**For further information, please contact:**

Peter Ejemyr, Group VP Corporate Communications, Elekta AB  
Tel: +46 733 611 000 (mobile), e-mail: [peter.ejemyr@elekta.com](mailto:peter.ejemyr@elekta.com)

**About Elekta**

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife<sup>®</sup> for non-invasive treatment of brain disorders and Elekta Synergy<sup>®</sup> for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTA. For more information about Elekta, please visit [www.elekta.com](http://www.elekta.com).